SG10201911837SA - Protease-resistant lipidated glp-1 analogs - Google Patents

Protease-resistant lipidated glp-1 analogs

Info

Publication number
SG10201911837SA
SG10201911837SA SG10201911837SA SG10201911837SA SG10201911837SA SG 10201911837S A SG10201911837S A SG 10201911837SA SG 10201911837S A SG10201911837S A SG 10201911837SA SG 10201911837S A SG10201911837S A SG 10201911837SA SG 10201911837S A SG10201911837S A SG 10201911837SA
Authority
SG
Singapore
Prior art keywords
analogs
protease
resistant
lipidated glp
glp
Prior art date
Application number
SG10201911837SA
Other languages
English (en)
Inventor
Jefferson Revell
Maria Bednarek
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of SG10201911837SA publication Critical patent/SG10201911837SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
SG10201911837SA 2015-06-10 2016-06-09 Protease-resistant lipidated glp-1 analogs SG10201911837SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562173631P 2015-06-10 2015-06-10
US201662343390P 2016-05-31 2016-05-31

Publications (1)

Publication Number Publication Date
SG10201911837SA true SG10201911837SA (en) 2020-01-30

Family

ID=56235790

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201911837SA SG10201911837SA (en) 2015-06-10 2016-06-09 Protease-resistant lipidated glp-1 analogs

Country Status (25)

Country Link
US (3) US10414811B2 (enExample)
EP (2) EP3865504A1 (enExample)
JP (1) JP6811190B2 (enExample)
KR (1) KR20180016441A (enExample)
CN (1) CN108271373B (enExample)
AU (2) AU2016277449B2 (enExample)
CA (1) CA2988841C (enExample)
CL (1) CL2017003144A1 (enExample)
CO (1) CO2017012675A2 (enExample)
CR (1) CR20170559A (enExample)
DO (1) DOP2017000287A (enExample)
EA (1) EA036415B1 (enExample)
ES (1) ES2849950T3 (enExample)
IL (1) IL255978B (enExample)
MX (1) MX389407B (enExample)
MY (1) MY185816A (enExample)
NI (1) NI201700156A (enExample)
NZ (1) NZ738909A (enExample)
PE (1) PE20180659A1 (enExample)
PH (1) PH12017502259A1 (enExample)
SG (1) SG10201911837SA (enExample)
SV (1) SV2017005585A (enExample)
TN (1) TN2017000519A1 (enExample)
TW (1) TWI726889B (enExample)
WO (1) WO2016198544A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3025592A1 (en) * 2016-06-09 2017-12-14 Medimmune Limited Protease-resistant mono-lipidated peptides
MA50047A (fr) * 2017-10-31 2020-07-08 Medimmune Ltd Administration orale d'analogues peptidiques de glp-1
PE20211417A1 (es) 2018-04-05 2021-08-02 Sun Pharmaceutical Ind Ltd Analogos novedosos de glp-1
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
WO2023044290A1 (en) 2021-09-15 2023-03-23 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
TW202346323A (zh) * 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的glp—1及升糖素雙重激動肽

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
CA2497794A1 (en) 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
CN101010339B (zh) * 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
BRPI0615573A2 (pt) * 2005-09-08 2011-05-24 Tufts College análogos de glp-1 estabilizados
EP1854455B1 (en) * 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
EP2021014A1 (en) 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
WO2008023050A1 (en) 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
DE602008005596D1 (de) 2007-06-21 2011-04-28 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
CA2707448C (en) 2007-12-11 2014-10-14 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
US8685895B2 (en) * 2008-12-05 2014-04-01 Carolyn Enever Methods for selecting protease resistant polypeptides
CN102459325B (zh) 2009-06-16 2015-03-25 印第安纳大学科技研究有限公司 胃抑胜肽受体活化的胰高血糖素化合物
WO2011048614A2 (en) 2009-10-22 2011-04-28 Cadila Healthcare Limited Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
EP2569000B1 (en) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
US20130143800A1 (en) 2011-11-07 2013-06-06 Research Development Foundation Combination therapies to treat diabetes
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
WO2014088631A1 (en) * 2012-12-06 2014-06-12 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
HK1220383A1 (zh) * 2013-03-14 2017-05-05 Medimmune Limited 用於治疗肥胖症的聚乙二醇化的胰高血糖素和glp-1共激动剂
SG10201805039UA (en) 2013-12-13 2018-07-30 Medimmune Ltd Protease resistant peptides

Also Published As

Publication number Publication date
SV2017005585A (es) 2018-05-22
AU2019229424A1 (en) 2019-10-03
IL255978B (en) 2021-04-29
EP3307769B1 (en) 2020-12-02
CO2017012675A2 (es) 2018-02-28
EP3307769A1 (en) 2018-04-18
CN108271373A (zh) 2018-07-10
PH12017502259A1 (en) 2018-06-25
EP3865504A1 (en) 2021-08-18
NZ738909A (en) 2019-08-30
JP6811190B2 (ja) 2021-01-13
CA2988841A1 (en) 2016-12-15
TWI726889B (zh) 2021-05-11
EA036415B1 (ru) 2020-11-09
CN108271373B (zh) 2021-12-28
KR20180016441A (ko) 2018-02-14
CL2017003144A1 (es) 2018-04-13
TN2017000519A1 (en) 2019-04-12
AU2016277449B2 (en) 2019-06-20
US20180162920A1 (en) 2018-06-14
CR20170559A (es) 2018-05-11
NI201700156A (es) 2018-10-18
TW201710287A (zh) 2017-03-16
MY185816A (en) 2021-06-10
MX2017015482A (es) 2018-02-09
US20200079833A1 (en) 2020-03-12
DOP2017000287A (es) 2018-04-15
US10414811B2 (en) 2019-09-17
ES2849950T3 (es) 2021-08-24
AU2016277449A1 (en) 2018-02-01
MX389407B (es) 2025-03-20
CA2988841C (en) 2023-06-06
EA201792640A1 (ru) 2018-06-29
IL255978A (en) 2018-01-31
US20210221866A1 (en) 2021-07-22
PE20180659A1 (es) 2018-04-17
JP2018518485A (ja) 2018-07-12
WO2016198544A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
PT3326358T (pt) Câmara multiview
GB201510019D0 (en) Compounds
GB201409967D0 (en) Gripper mechanism
IL255978B (en) Protease-resistant lipotransduction analogs of glp-1
GB201515730D0 (en) Motion platform
GB201508747D0 (en) Compounds
GB201514928D0 (en) PDD compounds
IL273387A (en) Thylanstatin analogs
GB201514751D0 (en) Compounds
GB2539762B (en) Connection mechanism
GB201505800D0 (en) Motion arrangement
GB201503828D0 (en) Redundancy scheme
ZA201901095B (en) Insulin analogs
GB201508864D0 (en) Compounds
PL3257657T3 (pl) Struktura zapobiegająca wyciekaniu
GB201510493D0 (en) Compounds
GB2527561B (en) Multilayer structure
GB2560466B (en) Freewheel mechanism
PT3350149T (pt) Compostos terminados com[(2-etoxi-5-trans-1-propen-1-il)-fenoxil]
GB201503926D0 (en) Compounds
GB201501115D0 (en) Compounds
GB2536290B (en) Self-weigh mechanism for office chair
HK1249120A1 (en) Protease-resistant lipidated glp-1 analogs
GB201508857D0 (en) Compounds
GB2537506B (en) Retaining mechanism